ClinicalTrials.gg
CompletedNCT03463499Updated Oct 27, 2022

The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients

An interventional study of Hyaluronic Acid and Chondroitin Sulfate in Interstitial Cystitis, sponsored by Samsung Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-10-27.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Sep 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Cystitis, Interstitial with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Cystitis, Interstitial · Korea, Republic of.

Started
2017
the only one that year
No phase
4 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
5 of 13
Samsung Medical Center

Among the 13 studies in Cystitis, Interstitial with a site in Korea, Republic of, this one is the only one that started in 2017, is one of 4 with no phase, and was the 9th registered.

Cystitis, Interstitial

236 studies on the registry are indexed under Cystitis, Interstitial; 35 are open to participants now.

Browse Cystitis, Interstitial studies →

Open to participants now

1 of the 13 studies in Cystitis, Interstitial with a site in Korea, Republic of is open now. Recruiting first, the newest first:

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 25 Cystitis, Interstitial studies recruiting now, 15 (60%) set no upper age limit and 5 (20%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cystitis, Interstitial with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of Hunner lesion in interstitial cystitis/bladder pain syndrome patients. To analyze the number and timing of recurrence based on a long-term follow-up.

03

Conditions studied

  • Interstitial Cystitis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female aged 20 yrs or greater
  2. Patients diagnosed with Hunner lesion in IC(interstitial cystitis)/BPS(Bladder Pain Syndrome) and who is scheduled to undergo transurethral resection
  3. Symptom persisted more than 6 months
  4. Pain VAS ≥4

Exclusion criteria

Exclusion Criteria:

  1. History of augmentation cystoplasty or previous transurethral coagulation/resection due to IC/BPS
  2. , pregnant or nursing women.
  3. Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.
  4. Urinary tract infection during run-in periods.
  5. Genitourinary tuberculosis or bladder,urethral and prostate cancer
  6. Recurrent urinary tract infection
  7. History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or Cesarean section,prostate operation or treatment etc within 6months.
  8. Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.-
  9. Using a indwelling catheter or execution of intermittent self catheterization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Hyaluronic Acid and Chondroitin Sulfate

    Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.

    Drug: Hyaluronic Acid and Chondroitin Sulfate

Interventions

  • DrugHyaluronic Acid and Chondroitin Sulfate

    Drug pages: Hyaluronic Acid · Chondroitin Sulfates

    Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.

06

What researchers measure

Primary outcomes

  1. change in recurrence rate in Hyaluronic Acid and Chondroitin Sulfate instillation group after transurethral resection treatment

    Time frame: Every 3 months for 2 years

Secondary outcomes

  1. changes in mean number of daytime frequency episodes

    Time frame: Every 3 months for 2 years

  2. changes in mean number of nocturia episodes

    Time frame: Every 3 months for 2 years

  3. changes in mean number of urgency episodes

    Time frame: Every 3 months for 2 years

  4. Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)

    Time frame: Every 3 months for 2 years

  5. Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF)

    Time frame: Every 3 months for 2 years

  6. Score of Global Response Assessment (GRA)

    Time frame: Every 3 months for 2 years

  7. Patient Global Assessment

    Time frame: at the end of the treatment(2 years)

  8. Occurrence of adverse event

    Time frame: Every 3 months for 2 years

07

Study locations

1 site
  • Samsung Medical Center, Sungkyunkwan University School of Medicine
    Seoul, 135-710, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2019, 24 months.

Of 35 non-industry interventional studies with no phase under Cystitis, Interstitial, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 24 months is close to that.

Counting every sponsor, half of 39 studies reached it within 23 months; a quarter within 16 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2018
First posted
Mar 13, 2018
StartActual
Sep 22, 2017
Primary completionActual
Sep 30, 2019
CompletionActual
Dec 31, 2021
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03463499
Responsible party
KYU-SUNG LEE (professor, Samsung Medical Center) — Principal investigator
First posted
Mar 13, 2018
Start date
Sep 22, 2017
Primary completion
Sep 30, 2019
Completion
Dec 31, 2021
Last update
Oct 27, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hyaluronic Acid · Chondroitin Sulfates

Start the discussion